trial

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

NCTId NCT07305779
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 12 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2025-05-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2025-03-07
Primary completion
2025-05-03
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
SEP-380135Quinidine Gluconate

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

1 total
Overland Park, United States

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2025-05-03
Status
COMPLETED
relationships
The graph out of here
drug
SEP-380135
drug
Quinidine Gluconate
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication